Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLFOX or FOLFIRI + bevacizumab or cetuximab
- Development stage
- Unknown
- Lead developer
- Korea Cancer Center Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This chemotherapy regimen is a specific treatment protocol evaluated in a Phase II clinical trial (NCT01810718) by the Korea Cancer Center Hospital for patients with rectal cancer and synchronous liver or lung metastases. The regimen consists of a chemotherapy backbone—either FOLFOX (oxaliplatin, leucovorin, and 5-fluorouracil) or FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil)—which may be combined with the VEGF inhibitor bevacizumab or the EGFR inhibitor cetuximab (specifically for patients with KRAS wild-type tumors). This intensive systemic therapy is administered following short-course radiotherapy (SCRT) and prior to delayed surgery, designed to control metastatic spread and downstage the primary tumor.
- Other names
- chemotherapy-Korea Cancer Center Hospital-rectal cancer-liver metastases-lung metastases
02
Targets
TS (Thymidylate synthase)EGFR (Epidermal growth factor receptor)TOP1 (DNA Topoisomerase I)DNAVEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on FOLFOX or FOLFIRI + bevacizumab or cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLFOX or FOLFIRI + bevacizumab or cetuximab.